Evaluation of MAQ-001 Monotherapy and Combination Therapy in Advanced Cancers with Approved Immune Checkpoint Blockade Options

The primary objective of this study is to evaluate the **safety** of MAQ-001 as both a monotherapy and in combination therapy in patients with **advanced cancers**. This is clinically relevant as it aims to determine the tolerability and potential adverse effects of MAQ-001, which could inform its future use in treatment regimens for cancers where immune checkpoint blockade is an approved option. The study focuses on advanced cancer histologies, including metastatic melanoma, lung cancer, renal cell carcinoma, Hodgkin’s lymphoma, microsatellite instability-high colon cancer, hepatocellular carcinoma, and gastric cancer.

The clinical trial involves participants diagnosed with **advanced cancer histologies** for which immune checkpoint blockade is an approved treatment option. These include conditions such as metastatic melanoma, lung cancer, renal cell carcinoma, Hodgkin’s lymphoma, microsatellite instability-high colon cancer, hepatocellular carcinoma, and gastric cancer. The study population comprises both male and female subjects, with an age range that includes adults and older adults. The trial does not specifically target a vulnerable population. However, the total number of participants has not been disclosed by the sponsor. The selection of the trial population does not emphasize any particular lifestyle considerations such as diet, physical activity, or habits.

The clinical trial is designed to evaluate the safety of **MAQ-001** as both a monotherapy and in combination therapy for patients with advanced cancers, including metastatic melanoma, lung cancer, renal cell carcinoma, Hodgkin's lymphoma, microsatellite instability-high colon cancer, hepatocellular carcinoma, and gastric cancer. This trial is structured as a Phase 1 study, which typically involves a small number of participants to assess safety, dosage, and side effects. The trial will employ a randomized, double-blind, controlled design to ensure unbiased results and reliable data collection. The estimated recruitment start date is January 31, 2024, with an anticipated end date of February 13, 2028, indicating a total trial duration of approximately four years.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on specific criteria. Following successful screening, participants will be enrolled in the study and will attend regular follow-up visits to monitor their health status, treatment response, and any adverse events. These visits are crucial for collecting data on the safety and efficacy of the investigational product. The end-of-study visit will mark the conclusion of a participant's involvement, during which final assessments will be conducted to gather comprehensive data on the long-term effects of the treatment.

The expected length of participant involvement will vary depending on individual response to treatment and the specific protocol of the trial. However, participants are generally expected to remain in the study for the duration of the trial unless specific conditions necessitate early termination. Such conditions may include significant adverse reactions, disease progression, or withdrawal of consent by the participant. The trial is conducted under strict ethical guidelines and regulatory standards to ensure the safety and well-being of all participants throughout the study period.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the lack of specific information, additional relevant details about drug administration, dosing schedules, and participant compliance monitoring are also not included. The absence of data on the experimental and non-experimental treatments limits the ability to provide a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, which typically focuses on assessing safety, tolerability, and pharmacokinetics, but may also include preliminary efficacy assessments. The trial is scheduled to commence recruitment on January 31, 2024, with an estimated completion date of February 13, 2028. Although specific efficacy endpoints are not detailed, Phase 1 trials often utilize various parameters such as biomarker levels or symptom improvement scores to gather initial efficacy data. The methods for measuring and analyzing these parameters are not specified, but they generally involve validated scales, laboratory tests, or patient-reported outcomes collected at predetermined timepoints. The trial will adhere to rigorous standards to ensure the reliability and validity of the efficacy data collected.